📊 EMBC Key Takeaways
Is Embecta Corp. (EMBC) a Good Investment?
Embecta demonstrates strong operational profitability (24.5% operating margin) with net income growing 21.8% YoY despite a 3.8% revenue decline, indicating solid cost management in a medical devices business. However, the severely stressed balance sheet with -$626.1M negative stockholders equity and $1.3B debt load—characteristic of a recent spin-off structure—presents significant financial risk that outweighs strong fundamentals absent revenue stabilization.
Embecta shows strong underlying profitability, with high gross and operating margins and improving net income despite a modest revenue decline. However, the balance sheet is a clear constraint: long-term debt is very high relative to the asset base, stockholders' equity is deeply negative, and free cash flow conversion is weak versus reported earnings. The business appears operationally solid, but financial health and growth quality are not strong enough to support a more bullish fundamental view.
Why Buy Embecta Corp. Stock? EMBC Key Strengths
- Excellent interest coverage (24.1x) and strong debt servicing capability
- Operating margin expansion to 24.5% with growing net income (21.8% YoY) and EPS (20.9% YoY)
- Positive free cash flow ($47.2M) with healthy liquidity metrics (2.46x current ratio, 1.68x quick ratio)
- Capital-light business model requiring minimal capex ($1.1M)
- High profitability, including 61.9% gross margin and 31.9% operating margin
- Net income and diluted EPS grew more than 20% year over year despite lower revenue
- Liquidity is adequate, with a 2.64x current ratio, 1.87x quick ratio, and strong 17.0x interest coverage
EMBC Stock Risks: Embecta Corp. Investment Risks
- Critical: Negative stockholders equity of -$626.1M creates substantial financial distress and limits strategic flexibility
- Declining revenue trend (-3.8% YoY) in medical devices sector threatens debt service sustainability
- High leverage with $1.3B debt against $1.0B total assets; balance sheet vulnerable to operational underperformance
- Revenue declined 3.8% year over year, raising concern about underlying demand or pricing pressure
- Negative stockholders' equity and $1.35B in long-term debt indicate a highly stressed capital structure
- Operating cash flow and free cash flow are modest relative to net income, suggesting weaker earnings-to-cash conversion
Key Metrics to Watch
- Revenue growth trajectory—stabilization or acceleration required to justify leverage
- Operating cash flow sustainability and debt reduction progress
- Gross margin maintenance amid potential pricing pressure in medical devices
- Revenue growth and volume trends
- Operating cash flow and debt reduction progress
Embecta Corp. (EMBC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.46x current ratio provides a solid financial cushion.
EMBC Profit Margin, ROE & Profitability Analysis
EMBC vs Healthcare Sector: How Embecta Corp. Compares
How Embecta Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Embecta Corp. Stock Overvalued? EMBC Valuation Analysis 2026
Based on fundamental analysis, Embecta Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Embecta Corp. Balance Sheet: EMBC Debt, Cash & Liquidity
EMBC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Embecta Corp.'s revenue has remained relatively flat over the 5-year period, with a 4% decline. The most recent EPS of $1.22 reflects profitable operations.
EMBC Revenue Growth, EPS Growth & YoY Performance
EMBC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $221.8M | -$4.1M | $-0.07 |
| Q1 2026 | $261.2M | N/A | $0.00 |
| Q3 2025 | $272.5M | $14.7M | $0.25 |
| Q2 2025 | $259.0M | $23.5M | $0.40 |
| Q1 2025 | $261.9M | N/A | $0.00 |
| Q3 2024 | $272.5M | $14.7M | $0.25 |
| Q2 2024 | $277.1M | $14.0M | $0.24 |
| Q1 2024 | $275.7M | $20.1M | $0.35 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Embecta Corp. Dividends, Buybacks & Capital Allocation
EMBC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Embecta Corp. (CIK: 0001872789)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EMBC
What is the AI rating for EMBC?
Embecta Corp. (EMBC) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EMBC's key strengths?
Claude: Excellent interest coverage (24.1x) and strong debt servicing capability. Operating margin expansion to 24.5% with growing net income (21.8% YoY) and EPS (20.9% YoY). ChatGPT: High profitability, including 61.9% gross margin and 31.9% operating margin. Net income and diluted EPS grew more than 20% year over year despite lower revenue.
What are the risks of investing in EMBC?
Claude: Critical: Negative stockholders equity of -$626.1M creates substantial financial distress and limits strategic flexibility. Declining revenue trend (-3.8% YoY) in medical devices sector threatens debt service sustainability. ChatGPT: Revenue declined 3.8% year over year, raising concern about underlying demand or pricing pressure. Negative stockholders' equity and $1.35B in long-term debt indicate a highly stressed capital structure.
What is EMBC's revenue and growth?
Embecta Corp. reported revenue of $483.0M.
Does EMBC pay dividends?
Embecta Corp. pays dividends, with $17.8M distributed to shareholders in the trailing twelve months.
Where can I find EMBC SEC filings?
Official SEC filings for Embecta Corp. (CIK: 0001872789) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EMBC's EPS?
Embecta Corp. has a diluted EPS of $0.67.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EMBC a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Embecta Corp. has a HOLD rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EMBC stock overvalued or undervalued?
Valuation metrics for EMBC: ROE of N/A (sector avg: 15%), net margin of 8.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EMBC stock in 2026?
Our dual AI analysis gives Embecta Corp. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EMBC's free cash flow?
Embecta Corp.'s operating cash flow is $48.3M, with capital expenditures of $1.1M. FCF margin is 9.8%.
How does EMBC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 8.3% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.46 (avg: 2).